Moderna Rebrands Cancer Breakthrough to Escape Vaccine Stigma

Amidst rising vaccine skepticism and shifting political climates, Moderna and Merck are strategically distancing their mRNA cancer treatments from the 'vaccine' label. This rebranding to 'Individualized Neoantigen Therapy' (INT) highlights a crucial industry trend where semantic framing is used to protect medical innovation from social and political polarization.